The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
May 14th 2025
The announcement came shortly before updated results from the SURMOUNT-5 clinical trial, which found Zepbound had superior weight-loss effects over Wegovy.
FDA Expands Indication of ALL Treatment for Patients with Increased Relapse Risk
March 30th 2018Officials with the FDA have expanded the approval of Amgen's blinatumomab (Blincyto) to include the treatment of adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.
Read More